The effect of Celecoxib on depression in patients with COVID-19

Investigating the effect of Celecoxib on depression induced by COVID-19: A randomized double blind and placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N142

Enrollment

Registered

2022-03-01

Start date

2022-05-22

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Patients treated with Celecoxib 100 mg BID for 6 weeks. Intervention 2: Control group: Patients treated with placebo BID for 6 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 60 years At least 20 days after the onset of symptoms and 7 days after the last day the patient was symptomatic, the patient should show a score of 14-17 on HDRS (moderate depression)

Exclusion criteria

Exclusion criteria: History of depression before infected with COVID-19 Psychosis Any other mental disorder in another axis Taking other psychiatric drugs which can alter cognitive functions History of ECT in recent two months Thyroid dysfunctions Kidney disease Liver disease History of cognitive dysfunction or dementia Pregnant or lactating women Serious suicidal thoughts (<2 in suicidal HDRS section)

Design outcomes

Primary

Measure	Time frame
Severity of Depression. Timepoint: by Hamilton Depression Rating Scale (HDRS). Method of measurement: Baseline and weeks 3 and 6.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026